



Prescription Drug Monitoring Program (PDMP) Overview and Strategy

Adam Nitenson, PhD

Health Research Project Director

RI PDMP

March 2022



RIDOH PDMP TEAM



Collette Onyejekwe
Pharm D

**Chief Health Program
Evaluator**

Adam Nitenson
PhD

**Health Research
Project Director**

Benjamin Hallowell
PhD

Biostatistician



RIDOH PDMP TEAM



Taylor Paiva
MPH
Epidemiologist



Victoria Ayers
Administrative
Technician



Angela Phengsavatdy
MPH
Administrative
Technician



RIDOH PDMP TEAM



Special Thanks
James McDonald
MD, MPH



RI PDMP OVERVIEW

Summary

- The Rhode Island PDMP collects data on all controlled substances (schedules II-V) and opioid agonist prescriptions that are dispensed by retail pharmacies with a controlled substance registration in Rhode Island or to Rhode Island residents.

Data Availability

- Complete data exists from April 1, 2016 to present.
- Incomplete data exist from February 2010 to March 2016.
- 9,823 registered prescribers and delegates; 723 registered pharmacies; 1,431 registered pharmacists and delegates

General Limitations

- This dataset only contains information for drugs that are dispensed, rather than all that are prescribed (24 hour required reporting period).
- Does not indicate if the medications were taken as prescribed.
- Does not capture in-office (as opposed to pharmacy) dispensed prescriptions (e.g. MAT)



RI PDMP OVERVIEW

Data Variables

Patient name, DOB, sex, address, payment type

- Prescriber name, ID
- Dispensing pharmacy name and address
- Dispenser name and ID
- Prescription information
 - Product name
 - National Drug Code (NDC)
 - Days supply
 - Refill count
 - Date written
 - Date filled
 - ICD-10 (International Classification of Disease) diagnosis code (as of 2020)



RI PDMP OVERVIEW

Opioid-specific Data Variables

- Prior opioid prescriptions
- Days on opioids
- Number of opioid prescriptions
- Provider Count
- Pharmacy Count
- Daily Morphine Milligram Equivalents (MME)
- Overlapping benzodiazepines and opioids
- Daily MME >100
- Active prescription at time of overdose



RI PDMP SAMPLE

Doe, John, 42M [Refine Search](#)

[Contact the Bamboo Health Knowledge/Help Center](#)

Date of Birth:
01/01/1980

Recent Address:
101 Fake Street Providence, RI 02901

[View Linked Records \(2\)](#) ^

Report Criteria

First Name: John
Last Name: Doe
DOB: 01/01/1980

Linked Records

Name: John Doe
DOB: 01/01/1980
ID: 1
Gender: Male
Address: 101 Fake Street Providence, RI 02901

Name: John Doe
DOB: 01/01/1980
ID: 2
Gender: Male
Address: 101 Fake Street Providence, RI 02901

Report generated on **07/18/2022**. Report Date Range: 07/18/2019 - 07/18/2022

PDF Report

Share

Export v

RX Summary

Summary

Total Prescriptions 2
Total Private Pay 0
Total Prescribers 1
Total Pharmacies 1

Opioids* (excluding Buprenorphine)

Current Qty 0
Current MME/day 0.00
30 Day Avg MME/day 0.00

Buprenorphine*

Current Qty 0
Current mg/day 0.00
30 Day Avg mg/day 0.00

Prescriptions

Total: 2 | Private Pay: 0

Showing 1-2 of 2 Items

View

15 Items

< 1 of 1 >

Filled	Drug	QTY	Days	Prescriber	Dispenser	PMP
09/27/2019	Oxycodone-Acetaminophen 5-325	360.00	30	Fa Doc	Rho (8953)	RI
09/07/2019	Oxycodone-Acetaminophen 5-325	30.00	30	Fa Doc	Rho (8953)	RI

[Disclaimer](#)

Showing 1-2 of 2 Items

View

15 Items

< 1 of 1 >

Providers

Total: 1

Showing 1 Item

View

15 Items

< 1 of 1 >

Name	Address	City	State	Zipcode	Phone
Family Doctor					-

Showing 1 Item

View

15 Items

< 1 of 1 >

Pharmacies

Total: 1

Showing 1 Item

View

15 Items

< 1 of 1 >

Name	Address	City	State	Zipcode	Phone
Rhode Island Pharmacy (8953)	1234 Rd	Providence	RI	02901	-

Showing 1 Item

View

15 Items

< 1 of 1 >




RI PDMP MILESTONES

- 2012: Prescription Drug Monitoring Program (PDMP) established in Rhode Island
- 2014: Law passed requiring all practitioners who hold an active Controlled Substance Registration (CSR) to register for the PDMP.
- 2016: All practitioners automatically registered within the PDMP.
- 2019: Bureau of Justice Assistance (BJA) grant awarded to RIDOH
 - \$2M over 3 years
- 2020: RI requires ICD-10 codes for all controlled substance prescriptions.
- 2022: Launch of Prescriber Report module



PDMP AND OPIOID DATA

Overdose Deaths by **Drug Type**, 2009 to 2021



Note: Data updated biannually

Note: Counts may not add to annual totals due to missing case information

Note: Prescription medications include prescription opioids such as oxycodone, hydrocodone, and benzodiazepines. Illicit drugs include substances such as heroin, illicit fentanyl, and cocaine.


■ Combination ■ Prescription Drugs ■ Illicit Drugs

Source: Prevent Overdose RI



PDMP AND OPIOID DATA

Number of Opioid Prescriptions Dispensed, 2017 to 2022



Note: Data updated quarterly


Note: Prescriptions for buprenorphine medication-assisted treatment for opioid use disorder are excluded from this measure.

Note: On November 1, 2019, the PDMP data were revised to reflect updates to the PDMP data analysis protocol, including revised methods for removing veterinary prescriptions, matching patients, and querying drug types.



PDMP AND OPIOID DATA

Number of People Prescribed Overlapping Opioid and Benzodiazepine Prescriptions, 2017 to 2022



Note: Data updated quarterly

Note: On November 1, 2019, the PDMP data were revised to reflect updates to the PDMP data analysis protocol, including revised methods for removing veterinary prescriptions, matching patients, and querying drug types.

Note: Prescriptions for buprenorphine medication-assisted treatment for opioid use disorder are excluded from this measure.

Note: Data for overlapping opioid and benzodiazepine prescriptions are calculated differently by year or by quarter. Summing this quarterly data gives a higher number of people than the yearly prevention strategy metric on the Track Our Action Plan data page.



PDMP PRESCRIBER REPORTS

Sample State

Prescription Monitoring Program PMP Prescriber Report



Date: 9/3/2019
Name: Sample Provider
Role: Physician



Date Covered by this Report: 10/01/2018 - 03/31/2019
DEA #: ZZ1234567
Specialty: Sample Specialty

Total Prescribers Within
Your Specialty:
1,254

TOP MEDICATIONS PRESCRIBED

buprenorphine HCl/naloxone HCl	oxycodone HCl	gabapentin
--------------------------------	---------------	------------


■ You ✓ Peer Specialty Comparison






PDMP PRESCRIBER REPORTS


SEDATIVES




of Patients: 29




of Patients Peer: 57




STIMULANTS



of Patients: 9



of Patients Peer: 17



AT-RISK PATIENTS


Dangerous Combination		Multiple Providers	MME Threshold
Benzo + Opioid	Benzo + Opioid + Carisoprodol	Patients with 5 or more Prescribers	Patients Receiving Daily MME >= 90
9 You	15 You + Other Prescribers	4	7
0 You	0 You + Other Prescribers	Patients with 5 or more Pharmacies	Patients Receiving Daily MME >= 120
		3	3

PDMP USAGE

Patient Searches by You	Patient Searches by Your Delegate(s)	Your Total Patient Searches
104	592	696



PDMP FUNDING AND SUSTAINABILITY



BJA FY19 Grant \$2,000,000 → BJA FY22 Grant \$1,400,000



PDMP FUNDING AND SUSTAINABILITY – BJA FY22 Grant

Goal 1: Develop PDMP upgrades in pursuit of Medicaid Enterprise Systems (MES) certification

Goal	Objective	Deliverable	Year 1				Year 2				Year 3			
			Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Develop PDMP upgrades in pursuit of MES Certification	Achieve MES Certification status	Finalize action plan for MES Certification	X	X										
		Demonstrate Qualified PDMP status			X	X								
	Secure Medicaid Match Funding	Receive notice of Medicaid match funding						X						
		Complete MES Certification								X				
	Ensure ongoing sustainability of PDMP operation	Create continued sustainability plan									X	X	X	X



PDMP ADDITIONAL ANALYTICS

PharmD Academic Detailing (PhAD) Project

Geographical analysis of prescribing data to identify target population

- **ICD-10 Codes Project**

- Identify diagnoses associated with elevated rates of prolonged opioid use overall

Buprenorphine Manuscript

Identify patients who newly initiated buprenorphine treatment for OUD

Identify patient and prescribing factors that impact long-term treatment retention

Pharmacy Utilization Project

Examined PDMP utilization by RI pharmacists, factors that affect determination of PDMP utilization, barriers to utilization, and dispensing practices of controlled substance prescriptions after utilization



PDMP ADDITIONAL ANALYTICS

PDMP Annual Report

Examine prescribing patterns for opioids, benzodiazepines, and stimulants

Identifying optimal Buprenorphine Dosing

Examine buprenorphine dose among patients starting buprenorphine treatment to identify whether differences exist among long-term treatment engagement and health outcomes based on doses.

Predicting overdose risk

Examine whether specific demographic or prescription characteristics predict overdose risk (link to fatal overdose data)

Prescriber Reports

Examine utilization and effect on prescribing behavior



THANK YOU!
QUESTIONS/COMMENTS?